Company / Shareholders' Equity
Integra Lifesciences Holdings Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.0B
FY2025
5-year range
$1.0B / $1.8B
FY2021-FY2025
Trend
-32.5%
vs FY2024
Sector context
#84 of 161
Health Care
What the data says
At $1.0B, Integra Lifesciences Holdings's shareholders' equity ranks #84 of 161 in the Health Care sector. Shareholders' Equity has declined for 3 consecutive years, from $1.8B in FY2022 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of -7.2%.
Declined from $1.6B to $1.0B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -16.7%
- 5-Year CAGR
- -7.2%
- 10-Year CAGR
- -
Sector benchmark
#84 of 161 in Health CareTop 52% of 161This company $1.0B Sector average $5.1B
▼
-79.4% below sector average
Key checks
Key Insights
- Integra Lifesciences Holdings's shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -7.2%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 32.5% year-over-year.
- Ranks #84 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | -32.5% |
| FY2024 | $1.5B | -2.7% |
| FY2023 | $1.6B | -12.0% |
| FY2022 | $1.8B | +7.1% |
| FY2021 | $1.7B | +11.2% |
| FY2020 | $1.5B | +6.9% |
| FY2019 | $1.4B | +3.0% |
| FY2018 | $1.4B | +83.1% |
| FY2017 | $751.4M | +6.7% |
| FY2016 | $704.3M | -6.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026